逆行A型夹层与壁内血肿:TEVAR与开放手术的荟萃分析
该系统综述与研究级荟萃分析纳入24项研究共709例逆行A型壁内血肿或夹层患者,其中开放手术259例、TEVAR 450例。TEVAR的院内死亡与神经系统并发症低于开放手术,降主动脉假腔血栓形成及IMH消退率更高;两组长期死亡率与再干预需求无显著差异。
要点
- TEVAR院内死亡3.9%,低于开放手术的12.5%,差异有统计学意义。
- TEVAR神经系统并发症4.1%,低于开放手术的11.6%。
- TEVAR降主动脉假腔血栓形成及IMH消退率达97.4%,高于开放手术的72.0%。
核心结论
- TEVAR可能作为逆行A型IMH/夹层的安全可行替代方案,短期与长期结局令人满意。
- TEVAR与开放手术在长期死亡率和再干预需求上无显著差异。
- 仍需大规模研究明确TEVAR的作用及其相对开放手术的疗效。
研究设计与样本
- 系统综述与研究级荟萃分析,遵循PRISMA指南,采用DerSimonian-Laird随机效应模型。
- 检索PubMed、Ovid MEDLINE和EMBASE,时间范围为2000年1月1日至2025年3月31日。
- 纳入24项研究(1项对比研究、23项单臂研究),共709例患者:开放手术259例,TEVAR 450例。
- 研究已在PROSPERO前瞻性注册(注册号CRD42024594305)。
主要发现
- TEVAR院内死亡3.9%(95%CI 2.2-6.7;I²=0.0%),开放手术12.5%(95%CI 8.7-17.7;I²=20.6%),差异显著(logit事件率差-1.27;95%CI -1.94至-0.60)。
- 神经系统并发症(卒中、截瘫)TEVAR 4.1%(95%CI 2.2-7.4;I²=0.0%),开放手术11.6%(95%CI 7.6-17.2;I²=30.9%)。
- 降主动脉假腔血栓形成及IMH消退率TEVAR 97.4%(95%CI 88.3-99.5;I²=0%),开放手术72.0%(95%CI 51.5-86.2;I²=50.8%)。
- 长期死亡率与再干预需求两组间无显著差异。
临床怎么用
- 对逆行A型IMH/夹层,TEVAR可作为开放手术之外的微创选择,尤其关注短期死亡与神经系统并发症风险。
- 决策需结合患者解剖条件与团队经验,长期再干预风险仍需随访观察。
局限性
- 纳入研究以单臂研究为主(23/24),仅1项为直接对比研究。
- 采用研究级数据合并 event rate 间接比较,非患者级随机对照证据。
- 作者指出仍需大规模研究进一步明确TEVAR的疗效与定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Retrograde type A intramural haematoma (IMH) and aortic dissection are serious conditions requiring prompt surgical intervention. While open surgery is the traditional treatment, Thoracic Endovascular Aortic Repair (TEVAR) has emerged as a less invasive alternative. This meta-analysis compares the clinical outcomes of TEVAR versus open surgery for these conditions. METHODS: A systematic review and study-level meta-analysis were conducted using study-level data extracted from published reports and analyzed using DerSimonian-Laird random-effects model, in line with the PRISMA guidelines. The study was prospectively registered with PROSPERO (registration ID: CRD42024594305). Databases including PubMed, Ovid MEDLINE, and EMBASE were searched for studies reporting outcomes on either open aortic repair or TEVAR for retrograde type A IMH/dissection that were published between 1st January 2000 and 31st March 2025. We included literatures that did not directly compare the two modalities and then pooled the event rates for comparison. RESULTS: The meta-analysis included 24 studies-one comparative and 23 single-arm studies-with a total of 709 patients, comprising 259 who underwent open surgery and 450 who received TEVAR. The pooled in-hospital mortality was 3.9% (95% CI: 2.2-6.7; I 2 = 0.0%) for TEVAR and 12.5% (95% CI: 8.7-17.7; I 2 = 20.6%) for open surgery, showing a significant difference (logit event rate difference: -1.27; 95% CI: -1.94 to -0.60). TEVAR also showed fewer neurological complications, such as stroke and paraplegia (TEVAR: 4.1% [95% CI: 2.2 to 7.4]; I2 = 0.0% vs Open: 11.6% [95% CI: 7.6 to 17.2]; I2 = 30.9%), compared to open surgery. TEVAR also had a higher rate of false lumen thrombosis and IMH regression in the descending aorta (TEVAR: 97.4% [95% CI: 88.3 to 99.5]; I2 = 0% vs Open: 72.0% [95% CI: 51.5 to 86.2]; I2 = 50.8%). However, no significant differences were found in long-term mortality or the need for reintervention between the two groups. CONCLUSIONS: This meta-analysis synthesizes current evidence for the use of TEVAR in retrograde type A IMH/dissection and use available information on open surgery as a reference. Our results suggested that TEVAR may be a safe and feasible alternative, with satisfactory short-term and long-term outcomes. Further large-scale studies are needed to clarify TEVAR's role and its efficacy against open surgery.
引用
- Yang KJ, Chi NH, Yu HY, et al. Endovascular vs. open surgical repair in retrograde type a dissection & intramural hematoma: A study-level meta-analysis. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40991360. doi:10.1093/icvts/ivaf224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。